| SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19 I Vicenti, M Zazzi, F Saladini Expert Opinion on Therapeutic Patents 31 (4), 325-337, 2021 | 114 | 2021 |
| Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge F Picarazzi, I Vicenti, F Saladini, M Zazzi, M Mori Molecules 25 (23), 5695, 2020 | 78 | 2020 |
| Molecular tracing of SARS-CoV-2 in Italy in the first three months of the epidemic A Lai, A Bergna, S Caucci, N Clementi, I Vicenti, F Dragoni, AM Cattelan, ... Viruses 12 (8), 798, 2020 | 72 | 2020 |
| Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy I Vicenti, A Rosi, F Saladini, G Meini, F Pippi, B Rossetti, L Sidella, ... Journal of antimicrobial chemotherapy 67 (4), 984-987, 2012 | 70 | 2012 |
| Changing patterns in HIV‐1 non‐B clade prevalence and diversity in Italy over three decades* A Lai, C Riva, A Marconi, M Balestrieri, F Razzolini, G Meini, I Vicenti, ... HIV medicine 11 (9), 593-602, 2010 | 65 | 2010 |
| Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro I Vicenti, A Boccuto, A Giannini, F Dragoni, F Saladini, M Zazzi Virus research 244, 64-70, 2018 | 54 | 2018 |
| Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors A De Luca, S Di Giambenedetto, A Lo Presti, S Sierra, M Prosperi, E Cella, ... Open forum infectious diseases 2 (2), ofv043, 2015 | 52 | 2015 |
| Circulating SARS-CoV-2 variants in Italy, October 2020–March 2021 A Lai, A Bergna, S Menzo, G Zehender, S Caucci, V Ghisetti, F Rizzo, ... Virology journal 18, 1-5, 2021 | 42 | 2021 |
| Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting M Zazzi, M Prosperi, I Vicenti, S Di Giambenedetto, A Callegaro, ... Journal of Antimicrobial Chemotherapy 64 (3), 616-624, 2009 | 35 | 2009 |
| Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro F Dragoni, A Boccuto, F Picarazzi, A Giannini, F Giammarino, F Saladini, ... Antiviral research 175, 104708, 2020 | 34 | 2020 |
| Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose I Vicenti, M Basso, F Gatti, R Scaggiante, A Boccuto, D Zago, E Modolo, ... International Journal of Infectious Diseases 112, 40-44, 2021 | 33 | 2021 |
| Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 … I Vicenti, F Gatti, R Scaggiante, A Boccuto, D Zago, M Basso, F Dragoni, ... International Journal of Infectious Diseases 108, 176-178, 2021 | 33 | 2021 |
| The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS-CoV-2 replication in vitro A Gidari, S Sabbatini, E Schiaroli, S Bastianelli, S Pierucci, C Busti, ... Microorganisms 10 (7), 1475, 2022 | 31 | 2022 |
| SARS-CoV-2 infection of human ovarian cells: a potential negative impact on female fertility FP Luongo, F Dragoni, A Boccuto, E Paccagnini, M Gentile, T Canosi, ... Cells 11 (9), 1431, 2022 | 31 | 2022 |
| Agreement between an in‐house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV‐1 protease, reverse … F Saladini, A Giannini, A Boccuto, I Vicenti, M Zazzi Journal of Clinical Laboratory Analysis 32 (1), e22206, 2018 | 30 | 2018 |
| Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects I Vicenti, F Razzolini, F Saladini, L Romano, M Zazzi Clinical infectious diseases 44 (12), 1657-1661, 2007 | 30 | 2007 |
| Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters S Corvasce, M Violin, L Romano, F Razzolini, I Vicenti, A Galli, P Duca, ... Antiviral therapy 11 (3), 329-334, 2006 | 23 | 2006 |
| Development of a cell-based immunodetection assay for simultaneous screening of antiviral compounds inhibiting Zika and dengue virus replication I Vicenti, F Dragoni, A Giannini, F Giammarino, M Spinicci, F Saladini, ... SLAS DISCOVERY: Advancing the Science of Drug Discovery 25 (5), 506-514, 2020 | 20 | 2020 |
| Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor A Brai, A Boccuto, M Monti, S Marchi, I Vicenti, F Saladini, CI Trivisani, ... ACS Medicinal Chemistry Letters 11 (5), 956-962, 2020 | 20 | 2020 |
| Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 Omicron sublineages BA. 1 and BA. 2 L Fiaschi, F Dragoni, E Schiaroli, A Bergna, B Rossetti, F Giammarino, ... Viruses 14 (7), 1374, 2022 | 19 | 2022 |
